Actualités et vidéos - TITAN PHARMACEUTICALS INC.

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed. About Titan...

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”). The Company's stockholders approved the reverse stock split at a Special Meeting of...

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective...

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”). Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000,...

SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology. The Company’s addiction portfolio...

Signs Non-Binding Letter of Intent for Transformational Transaction Continues to Make Substantial Progress on Strategic Transactions Including Sale of Existing Assets SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to report that it has entered a non-binding letter of intent to complete a reverse merger with a leading developer in Advanced Air Mobility (AAM) (the “Proposed Reverse Merger”). Titan Chief...

Titan Pharmaceuticals Announces Board Expansion and Management Changes PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Board") from five (5) to eleven (11) and appointed six new directors following their election at its special meeting of stockholders held on August 15, 2022 (the "Special...

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant PR Newswire SOUTH SAN FRANCISCO, Calif., July 5, 2022 SOUTH SAN FRANCISCO, Calif. , July 5, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid...

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a...

Titan Pharmaceuticals to Explore Strategic Alternatives PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 SOUTH SAN FRANCISCO, Calif. , Dec. 21, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process. Potential strategic alternatives that...

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021 PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 SOUTH SAN FRANCISCO, Calif. , Nov. 8, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, Ben Land , Ph.D., Research Assistant Professor at the University of Washington's Department of Pharmacology, reported additional...

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021 PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura ® -based TP-2021 implant in an established animal model of chronic pruritus will be presented at the Society for Neuroscience 2021 Meeting, being held virtually, on November 8 . About Chronic Pruritus Chronic pruritus...

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus...

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement - Titan to Evaluate and Potentially Licence Tetrapeptide Kappa-Opioid Agonist Compounds for use in Combination with its ProNeura® Technology Platform - PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license...

Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K PR Newswire SOUTH SAN FRANCISCO, Calif., March 31, 2021 SOUTH SAN FRANCISCO, Calif. , March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC"). In October 2020 , Titan announced a strategic restructuring, including the discontinuation of its U.S....

...

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed for use in combination...

Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 SOUTH SAN FRANCISCO, Calif. , Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a registered direct offering and warrants to purchase common stock in a...

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("the "Company") today announced that on December 15, 2020 , it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq's minimum bid price requirement and is in compliance with all...

...